RxDoctor Payments Data

Rajesh Patel, MD

Urology · Homewood, ILNPI 1427145440

Payments from drug & device makers

$7,684in general payments, 2019–2025

Across 209 payments — averaging $36.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$1K
  • Boston Scientific$802
  • Intuitive Surgical$783
  • AbbVie$617
  • Axonics, Inc.$472
  • Astellas Pharma US Inc$409
  • plus $4K from 34 others

What the payments were for

  • Food & beverage$7,63599%
  • Education$401%
  • Gifts$90%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,684 in reported general payments places this provider in the 75th percentile of 550 urology providers in Illinois.

See all urology providers in Illinois

Medicare billing

Part B allowed, 2024
$480,146
Medicare patients
1,207
Services billed
8,007

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron80$71,905
GemtesaVibegron23$18,479
Tamsulosin Hcl575$9,589
Finasteride439$5,841
Silodosin42$3,684
Alfuzosin Hcl ErAlfuzosin Hcl71$1,939
Tolterodine Tartrate ErTolterodine Tartrate16$1,927
Potassium Citrate ErPotassium Citrate12$1,902
Dutasteride33$1,107
Tadalafil13$600
Oxybutynin Chloride ErOxybutynin Chloride43$595
Ciprofloxacin Hcl100$521
Solifenacin Succinate13$507
Ketorolac Tromethamine16$282
Sildenafil Citrate46$251

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$409$71,90580 claims
Sumitomo Pharma America, Inc.Gemtesa$355$18,47923 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 550 urology providers in Illinois.

Other urology in Homewood

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →